Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Yale Cancer Center · Smilow Cancer Hospital · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
6,511
total citations
- FWCI
- 248.18
- Percentile
- 100%
- References
- 34
Citations per year
Authors
19- RSRoy S. HerbstCorresponding
Yale Cancer Center, Smilow Cancer Hospital
- PBPaul Baas
Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute
- DKDong‐Wan Kim
Seoul National University Hospital
- EFEnriqueta Felip
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- JLJosé Luis Perez‐Gracia
Clinica Universidad de Navarra
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Docetaxel
- Medicine
- Lung cancer
- Internal medicine
- Population
- Oncology
- Cancer
No related works found for this paper.